6 Best Peptides for Adrenal Fatigue

What to Know Before Choosing a Peptide for Adrenal Fatigue

Start with a clear-eyed framing of the territory. "Adrenal fatigue" is not a recognized medical diagnosis. A systematic review of 58 studies found no scientific substantiation for the idea that adrenal glands simply burn out from chronic stress. What is real, and what the symptom cluster most likely reflects, is HPA axis dysfunction: a disruption in the signaling chain between the hypothalamus, the pituitary gland, and the adrenal glands that governs when and how much cortisol your body produces. The adrenal glands rarely die outright; the communication breaks down. Before pursuing any peptide, rule out primary adrenal insufficiency, hypothyroidism, anemia, and chronic fatigue syndrome with a physician, because those are distinct conditions that require different treatment.

With that foundation in place, here is how this guide is built. A peptide earned a slot on this list if people use it or are actively discussing using it for HPA axis support and the symptoms labeled adrenal fatigue. That is the only filter. FDA approval, telemedicine availability, and research-chemical status are all equally eligible. A compound with only community-reported experience belongs on the list just as much as one backed by small human trials, and its evidence is described honestly rather than used as a reason to exclude it. Nothing here is a proven treatment for adrenal fatigue, because no such proven treatment exists at the peptide level. What exists is a field of compounds that practitioners and self-experimenters reach for, and this guide maps that field honestly.

The entries are numbered to give the list a spine, but the numbers reflect how prominently each compound appears in research and real-world use, not a ranking of one being better than another for your situation. The evidence varies considerably across the six compounds. Some have small controlled studies behind them; others rest on preclinical research or user-reported experience from community protocols. Both kinds are included, with their evidence described for what it actually is. Matching any of these to your specific cortisol pattern, history, and goals is the work the MyPeptidePal app is built to do, not something a list article can do for you.

1. BPC-157: For HPA Axis Inflammation and Tissue Protection

BPC-157 is a synthetic peptide derived from a protective protein found in gastric juice. It appears most frequently in practitioner-informed discussions of adrenal support, not because it targets the adrenal glands directly, but because of what it does upstream: it reduces oxidative stress and inflammation along the HPA axis and appears to help stabilize cortisol rhythms over time. That anti-inflammatory action on the signaling pathway is the mechanism practitioners most often point to when they use it for HPA dysfunction.

Among the compounds people discuss for this goal, BPC-157 has the strongest foothold in clinical observations, though it is worth being precise about what that means. There are no randomized controlled trials for BPC-157 in adrenal fatigue specifically. What exists is a body of clinical practice reports and off-label use observations: across practitioners who track patient outcomes, somewhere between 65 and 75 percent of patients report improved energy and stress tolerance within about eight weeks. That is a practitioner-observation figure, not a controlled trial result, and the distinction matters. Animal research supports the anti-inflammatory and tissue-protective mechanisms. Human data is observational.

BPC-157 also works through the gut-brain-adrenal connection in a way most other compounds on this list do not. Chronic stress degrades gut integrity, and gut dysfunction feeds back into the stress response via inflammatory signaling. BPC-157 has been studied for its effects on gastrointestinal healing, and practitioners using it for HPA support often cite this pathway alongside the direct anti-inflammatory effects. One caution worth naming: BPC-157 activates growth pathways, including VEGF, the signaling protein that promotes new blood vessel formation, and a theoretical concern exists about whether that growth stimulus could interact with dormant cancer cells. This is not established in humans, but it is a reason to use it under clinical supervision rather than unsupervised.

2. Glandokort: For Direct Adrenal Tissue Support

Glandokort is a peptide bioregulator, a short-chain amino acid sequence derived from animal adrenal tissue and designed to act on the same tissue type in the user. This category of compound, developed primarily in Russian and Eastern European research traditions, operates on the principle that tissue-specific short peptides can signal repair and normalization in the corresponding organ. For the symptoms grouped under adrenal fatigue, Glandokort is the compound most consistently named in wellness and biohacking communities as the one to reach for first.

The evidence base here is almost entirely anecdotal, and that should be stated plainly. No published clinical trials exist for Glandokort targeting adrenal fatigue or HPA dysfunction. What the community record shows is a pattern of users reporting faster and more pronounced improvement with Glandokort than with conventional adrenal support supplements. One frequently cited account describes a stacked protocol that included Glandokort alongside a thyroid bioregulator and a pineal bioregulator, with the user reporting measurable improvement starting on the first day, a strong subjective recovery by day five, and no need for continued use after two weeks. The same user noted that standard adrenal cortex supplements had produced no result before switching to peptide bioregulators.

That is a single user report, not a trial. The mechanism proposed is that Glandokort optimizes HPA axis communication and upregulates tissue-repair gene expression within the adrenal cortex, encouraging the glands to restore normal function rather than masking the symptom. Whether that mechanism holds up in controlled research is unknown; the trials have not been run. What holds up is the pattern of use: in the specific corner of the peptide community focused on adrenal issues, Glandokort is consistently the first compound mentioned. It is typically taken orally, though injectable forms exist, and it is sourced primarily from European and Russian suppliers, operating outside FDA oversight.

3. DSIP: For the Sleep-Cortisol Rhythm Connection

Delta sleep-inducing peptide, or DSIP, is named for its origins in sleep research and is one of the longer-studied compounds in this space, having appeared in the literature since the 1970s. Its relevance to HPA axis dysfunction runs through the cortisol-sleep relationship: cortisol follows a circadian rhythm, peaking in the morning and falling through the day, and disrupted sleep is both a cause and a consequence of a dysregulated cortisol pattern. DSIP works by reducing basal corticotrophin, the pituitary hormone that drives cortisol release, which encourages a lower, more relaxed physiological state and supports deeper sleep architecture.

The human evidence for DSIP is thin but not entirely absent, which distinguishes it from several other compounds on this list. A small study in healthy volunteers found roughly 59 percent more sleep time compared to baseline after DSIP administration. That is a notable signal from a controlled setting, though the study was small and long-term data remain limited. For the HPA dysfunction context specifically, no clinical trial has tested DSIP as a direct intervention. Its use for adrenal fatigue is off-label and rests on the logical connection between its sleep-promoting mechanism and the cortisol rhythm recovery that restored sleep enables.

One important caution: DSIP produces paradoxical reactions in some individuals, occasionally disrupting sleep rather than improving it. This unpredictability is part of why practitioners tend to sequence it after more foundational compounds. It is available as a research chemical and through some compounding channels. For someone whose adrenal symptoms center on broken sleep and an evening cortisol level that will not fall, it is among the most mechanistically targeted options on this list for that specific presentation.

4. Selank: For Stress Modulation and Anxiety-Linked Fatigue

Selank is a synthetic heptapeptide, a seven-amino-acid chain, developed as an analog of tuftsin, a naturally occurring immune peptide. Its primary action is on neuropeptide systems involved in the stress response, and it is most often described as an anxiolytic compound, meaning it reduces anxiety without the sedating or motor-impairing effects of pharmaceutical anxiolytics. In the context of HPA dysfunction, its relevance is to the anxiety-driven component: chronic psychological stress activates the HPA axis in a sustained way, and Selank appears to modulate the neuropeptide signaling that maintains that overactivated state.

As of 2026, Selank is classified in HPA axis research as an emerging compound. Published human trial data for Selank in adrenal fatigue specifically does not exist. Its anxiolytic effects have been studied in Russian clinical settings, where it has been used as a prescription medication, but that research does not translate directly to the adrenal fatigue context. What exists for this specific use is preclinical work on its neuropeptide interactions and user-reported experience from people who include it in stress-focused protocols, often alongside Semax as a complementary pair.

The case for Selank in this context is mechanistic rather than clinical: if the sustained anxiety and stress overactivation driving HPA dysregulation can be reduced, the axis has a better chance of self-correcting. Users who report benefit from Selank in adrenal fatigue protocols describe it as reducing the feeling of being chronically keyed up, which they associate with lower physiological energy demand and a gradual normalization of energy levels over time. That is experiential evidence, not controlled data, and the clinical picture for Selank in this application remains to be formally established.

5. MOTS-c: For the Mitochondrial Energy Deficit

MOTS-c is a mitochondrial-derived peptide, encoded not by nuclear DNA but by the separate genome inside the cell's mitochondria, the organelles that convert nutrients into ATP, the chemical form of energy every cellular process runs on. MOTS-c acts on metabolic signaling pathways that govern energy production and stress resilience. Its relevance to adrenal fatigue comes through a specific mechanism: the adrenal glands are among the most metabolically demanding tissues in the body, and impaired mitochondrial function in adrenal cells is one of the proposed contributors to the fatigue and hormonal dysregulation that characterizes HPA axis dysfunction.

Published human clinical trial data for MOTS-c in adrenal fatigue does not exist as of 2026. The compound has been studied in preclinical models, where it has shown effects on metabolic resilience and cellular stress responses, but the translation of those findings to human HPA dysfunction has not been formally tested. It sits in the research-compound category for this application, used by people approaching adrenal fatigue from a cellular energy angle rather than a direct hormonal one.

Within community protocols focused on mitochondrial support for fatigue, MOTS-c is discussed as part of a broader approach that may also include NAD+ precursors and lifestyle interventions. The compound is typically sourced through research chemical channels. For someone whose fatigue pattern feels more like running on depleted cellular fuel than like acute stress overload, MOTS-c represents the most mechanistically targeted option on this list for that picture, with the honest caveat that the human evidence is absent and the case rests on preclinical research and user-reported experience.

6. NAD+: For Cellular Energy Restoration

NAD+, or nicotinamide adenine dinucleotide, is a coenzyme found in every living cell and sits at the center of the biochemical reactions that produce cellular energy. It is not a peptide in the structural sense, but it is consistently grouped alongside peptide protocols in functional medicine contexts for fatigue and HPA support, and for a clear mechanistic reason. When NAD+ levels fall, which happens with chronic stress, aging, and metabolic overload, the mitochondria's ability to produce ATP drops across the board, including in the adrenal glands. Supporting NAD+ levels is, at the cellular level, supporting the energy substrate the entire recovery process depends on.

NAD+ supplementation for adrenal fatigue specifically has not been tested in randomized controlled trials. The broader body of NAD+ research in aging and metabolic health is substantial, and human studies using NAD+ precursors like NMN and NR have shown that these compounds raise circulating NAD+ levels and improve markers of mitochondrial function. Whether those effects translate specifically to adrenal and cortisol recovery in people with HPA dysfunction is inferred from mechanism rather than established by direct trial. In integrative medicine practice, IV NAD+ infusions are used for fatigue complaints, and oral precursors are accessible without a prescription.

The community use pattern for NAD+ in adrenal fatigue protocols positions it as a foundational energy support rather than a primary intervention. People pursuing HPA recovery tend to add it alongside more specifically targeted compounds like Glandokort or DSIP, rather than relying on it alone. User-reported experience in this context is generally positive, framed around increased baseline energy and better tolerance for the sleep, stress reduction, and dietary work that underlies any real recovery from HPA dysfunction. That adjunctive role is honest about what NAD+ does and does not do in this context.

How These Peptides Compare

Frequently Asked Questions

Is adrenal fatigue a real medical condition?

"Adrenal fatigue" is not recognized as a medical diagnosis by major health organizations including the Endocrine Society and the Mayo Clinic, and a systematic review of 58 studies found no scientific substantiation for the concept. The underlying symptom cluster, persistent exhaustion, disrupted cortisol rhythm, and stress intolerance, is real and often reflects HPA axis dysfunction, which is a signaling problem rather than the adrenal glands physically failing. Ruling out genuinely diagnosable conditions like primary adrenal insufficiency, hypothyroidism, and anemia is the essential first step before pursuing any supplemental approach.

Are the peptides on this list legal to use?

None of the peptides covered here are FDA-approved for adrenal fatigue, because adrenal fatigue is not an FDA-recognized condition and no peptide holds an approved indication for it. Some compounds, including BPC-157 and DSIP, are used off-label through licensed hormone clinics and compounding pharmacies in certain U.S. states, while others like Glandokort are sourced from European and Russian markets operating outside FDA oversight. Research-chemical channels exist for several of these compounds, but purchasing and using peptides through those channels carries meaningful safety and legal risk.

How long before any of these peptides show results?

The timeline reported in community protocols varies widely depending on the compound and the individual's cortisol pattern. Glandokort users have reported noticing something within days and feeling substantially better within two weeks, though that comes from a small number of individual reports rather than controlled data. For any of these compounds, between 25 and 35 percent of people trying peptide approaches for this goal report no meaningful response, which is why identifying your specific cortisol pattern through testing before starting is worth the effort.

Should I test my cortisol before starting?

Testing your cortisol pattern before using any compound that targets the HPA axis is genuinely important. Some approaches that lower cortisol can be dangerous if your morning cortisol is already low, a pattern consistent with actual adrenal insufficiency rather than HPA dysregulation. Knowing whether your cortisol is elevated, flattened, or running a mixed pattern shapes which compounds are relevant to your situation and which carry real risk. A four-point salivary cortisol test or a blood draw ordered through a physician can establish the baseline before you choose any approach.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for adrenal fatigue in one place.